Recommendations for the management of herpes zoster.

  title={Recommendations for the management of herpes zoster.},
  author={Robert H. Dworkin and Robert W. Johnson and Judy Breuer and John W. Gnann and Myron J Levin and Miroslav Backonja and Robert F. Betts and Anne A. Gershon and Maija Haanpāā and Mike Mckendrick and Turo Nurmikko and Anne Louise Oaklander and Michael N. Oxman and Deborah Pavan-Langston and Karin Lottrup Petersen and Michael C. Rowbotham and Kenneth E. Schmader and Brett R. Stacey and Stephen K. Tyring and Albert J. M. van Wijck and Mark S Wallace and Sawko W. Wassilew and Richard J Whitley},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  volume={44 Suppl 1},
  • R. Dworkin, Robert W. Johnson, R. Whitley
  • Published 2007
  • Medicine, Psychology
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
The objective of this article is to provide evidence-based recommendations for the management of patients with herpes zoster (HZ) that take into account clinical efficacy, adverse effects, impact on quality of life, and costs of treatment. [] Key Method Systematic literature reviews, published randomized clinical trials, existing guidelines, and the authors' clinical and research experience relevant to the management of patients with HZ were reviewed at a consensus meeting. The results of controlled trials…

Figures and Tables from this paper

Antivirals for Management of Herpes Zoster Including Ophthalmicus: A Systematic Review of High-Quality Randomized Controlled Trials

Evidence from quality trials have shown significant reduction in risk of pain with valaciclovir and famciclovIR for management of herpes zoster including ophthalmicus.

Herpes zoster antivirals and pain management.

Herpes zoster in hospitalized adults: Practice gaps, new evidence, and remaining questions

Herpes Zoster Presentation, Management, and Prevention: A Modern Case-Based Review

  • L. Rosamilia
  • Medicine
    American Journal of Clinical Dermatology
  • 2019
In case-based form, these and other complex but common scenarios will be examined using clinical and viral mechanistic clues, along with updated treatment and prevention guidelines, to provide a modern HZ case management compendium, comprehensive of the diverse age and health populations now presenting with this condition.

Management and prevention of herpes zoster: A Canadian perspective.

  • G. BoivinR. JoveyC. T. ElliottD. Patrick
  • Medicine
    The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale
  • 2010
A live, attenuated zoster vaccine has been recently shown to significantly decrease herpes zoster incidence, postherpetic neuralgia (PHN) and the overall burden of illness when administered to adults older than 60 years of age.

Herpes zoster - is there a need for new treatment recommendations?

It is found no proof for the need to apply at least 7 days of acyclovir therapy for herpes zoster treatment in the studies that have been published so far and an association between therapy delay and unfavorable outcomes is unable to be proved.

Management of acute shingles (herpes zoster).

Practical, evidence-based recommendations for the management of acute shingles (herpes zoster) were published this year in Clinical Infectious Diseases and some of the research on which these guidelines are based is reviewed.

Herpes Zoster: Description of the Associated Burden and Its Preventive Strategies

The first HZ vaccine with proven efficacy thus promotes healthy ageing and improved quality of life and is effective in old, frail, co-morbid and poly-medicated patients.

Vaccination against herpes zoster in developed countries

Evidence is summarized regarding the burden of illness; vaccine efficacy and safety; and cost-effectiveness of vaccination, to assist evidence-based policy making and guide clinicians in their recommendations about the use of the zoster vaccine.

The prevention and management of herpes zoster

A live, attenuated VZV vaccine has proven to be efficacious in reducing the incidence of and morbidity associated with HZ and PHN in older adults, and the vaccine's efficacy has been shown to persist for at least 4 years, but is likely to last a lot longer.



Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials.

  • T. LancasterC. SilagyS. Gray
  • Medicine, Psychology
    The British journal of general practice : the journal of the Royal College of General Practitioners
  • 1995
A systematic review of existing trials, including meta-analysis, was performed to determine the efficacy of available therapies in reducing the incidence of postherpetic neuralgia and concluded that treatment during the acute phase of herpes zoster reduces pain later.

Zoster-associated chronic pain: an overview of clinical trials with acyclovir.

An overview of all the available placebo-controlled trial data for oral acyclovir in acute herpes zoster infection has confirmed that a dose of 800 mg five times daily for seven to ten days is

Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia?

There is limited evidence that current interventions prevent or shorten PHN, and Famciclovir and valacyclovir have been shown to reduce the duration of PHN in single published trials.

Acyclovir with and without Prednisone for the Treatment of Herpes Zoster

A clinical trial to determine the effect of adding corticosteroids to acyclovir for the treatment of herpes zoster and key study end points were measurements of pain and quality of life.

Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials.

Acyclovir was clearly shown to accelerate pain resolution by all of the measures employed, and benefit was especially evident in patients 50 years of age or older.

Varicella-zoster virus eye disease.

The laboratory and clinical studies have enhanced the knowledge of the varicella-zoster virus and increased the ability to treat this infection and the aftermath, but the authors are still far short of providing adequate therapy for patients who experience the severe forms of the disease.

Oral acyclovir in the treatment of herpes zoster in general practice.

Acyclovir reduced the extent and duration of the rash, the spread of the Rash to adjacent dermatomes and the incidence of disseminated lesions, and it shortened the period of new lesion formation and reduced the occurrence of ulceration in acute herpes zoster and postherpetic neuralgia.

The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis.

Treatment of herpes zoster with 800 mg/d of oral acyclovir within 72 hours of rash onset may reduce the incidence of residual pain at 6 months by 46% in immunocompetent adults.

Effect of oral acyclovir on pain resolution in herpes zoster: A reanalysis

It is found that the median duration of pain in acyclovir recipients was 20 days vs. 62 days for their placebo counterparts and the absence of pain at the onset of cutaneous herpes zoster did not preclude its later development.

Herpes zoster in children and adolescents.

The probability of postherpetic neuralgia in children and adolescents with herpes zoster is extremely low and it is seldom associated with undiagnosed malignancy in the primary care setting.